Krystal Biotech (NASDAQ:KRYS) Receives Buy Rating from Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Krystal Biotech (NASDAQ:KRYS - Free Report) in a research note published on Wednesday morning,Benzinga reports. They currently have a $212.00 price objective on the stock.

KRYS has been the subject of several other reports. William Blair raised shares of Krystal Biotech to a "strong-buy" rating in a report on Friday, August 30th. Stifel Nicolaus raised their price target on Krystal Biotech from $204.00 to $220.00 and gave the stock a "buy" rating in a report on Wednesday, September 11th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Krystal Biotech in a research note on Thursday, August 29th. HC Wainwright restated a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Wednesday. Finally, Citigroup lifted their target price on Krystal Biotech from $204.00 to $206.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $206.67.

Krystal Biotech Stock Performance

KRYS stock traded down $12.40 during mid-day trading on Wednesday, hitting $156.64. The company had a trading volume of 359,642 shares, compared to its average volume of 322,707. The firm has a market cap of $4.51 billion, a PE ratio of 88.50 and a beta of 0.80. Krystal Biotech has a 12 month low of $107.50 and a 12 month high of $219.34. The stock's fifty day moving average price is $181.01 and its two-hundred day moving average price is $185.37.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts' consensus estimates of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company had revenue of $83.84 million for the quarter, compared to analysts' expectations of $82.94 million. During the same quarter in the previous year, the firm posted ($0.67) EPS. Krystal Biotech's revenue was up 879.9% on a year-over-year basis. Equities analysts anticipate that Krystal Biotech will post 2.97 earnings per share for the current year.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares of the company's stock, valued at $243,195,835.96. This represents a 1.67 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 14.10% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Summit Trail Advisors LLC purchased a new position in shares of Krystal Biotech in the 3rd quarter worth about $1,893,000. Swiss National Bank boosted its stake in Krystal Biotech by 8.0% in the third quarter. Swiss National Bank now owns 39,100 shares of the company's stock worth $7,117,000 after buying an additional 2,900 shares in the last quarter. Sei Investments Co. grew its position in Krystal Biotech by 18.9% during the second quarter. Sei Investments Co. now owns 40,115 shares of the company's stock valued at $7,367,000 after acquiring an additional 6,363 shares during the last quarter. Shaker Investments LLC OH purchased a new position in shares of Krystal Biotech during the third quarter worth approximately $532,000. Finally, Citigroup Inc. lifted its holdings in shares of Krystal Biotech by 65.4% in the 3rd quarter. Citigroup Inc. now owns 35,084 shares of the company's stock worth $6,386,000 after acquiring an additional 13,874 shares during the last quarter. Institutional investors own 86.29% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).